Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sylentis S.A.
DescriptionShort interfering RNAs (siRNAs) against transient receptor potential vanilloid 1 (TRPV1; VR1)
Molecular Target Transient receptor potential vanilloid 1 (TRPV1) (VR1)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase II
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat discomfort associated with dry eye syndrome
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today